GlassScriptPhysician profile
Shannon Hudson
NPI 1548234701
$480.34
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.13 · 2020: $84.73 · 2021: $314.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $91.30 | 2019-2020 | |
| Evofem Biosciences, INC. | $86.71 | 2021 | |
| Antares Pharma, INC. | $61.95 | 2020-2021 | |
| Lupin INC. | $40.13 | 2019-2020 | |
| Scynexis, INC. | $33.05 | 2021 | |
| Myovant Sciences INC. | $28.00 | 2021 | |
| Clarus Therapeutics INC. | $23.07 | 2021 | |
| Mayne Pharma Commercial LLC | $22.68 | 2021 | |
| Boston Scientific Corporation | $19.92 | 2021 | |
| Myriad Genetic Laboratories, INC. | $18.56 | 2021 | |
| Avadel Specialty Pharmaceuticals, LLC | $17.00 | 2019 | |
| Merck Sharp & Dohme LLC | $13.79 | 2021 | |
| Agile Therapeutics, INC. | $12.50 | 2021 | |
| Avion Pharmaceuticals | $11.68 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Hudson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.